“Learn what the main classifications of lung diseases are: obstructive, restrictive, ventilation, and perfusion. Discover the classification of common diseases like asthma, emphysema, and pneumonia.” Learn more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ…
Types Of Pulmonary Diseases
The recently concluded Pulmonary Fibrosis Foundation (PFF)’s third biennial scientific conference, Summit 2015: From Bench to Bedside, achieved a record attendance of over 700 people — from pulmonary fibrosis researchers, academics and healthcare specialists to industry front-runners and PF patients/caregivers — representing 18 countries. Attendees presented research and discussed new treatments in a collaborative setting…
Veracyte, Inc.recently presented four abstracts on current diagnostic challenges related to interstitial lung disease (ILD) and the potential for improved diagnostic procedures using novel genomic-based strategies. The abstracts were given at the Pulmonary Fibrosis Foundation’s PFF Summit 2015: From Bench to Bedside at the JW Marriott Hotel…
A team of researchers report that a mouse’s age influences the ability of its mesenchymal stem cells to repair pulmonary fibrosis-induced damage, a finding with significant implications for stem cell therapies. The study, “Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis,”…
Colin was diagnosed with idiopathic pulmonary fibrosis. Watch the video to see his testimony. Learn more about IPF : https://bit.ly/1QiRmr3…
Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Neurogenic disorders are conditions associated with the central nervous…
Read the articles here: 1. Potential Therapy for Severe Lung Disease Advances at aTyr Pharma 2. New Anti-Fibrotic Drug Candidate MRG-201 Enters Phase 1 Clinical Trial 3. Genentech’s IPF Therapy Found to Improve Lung Function over Time…
The nonprofit phaware global association (phaware), an organization focused on raising awareness of pulmonary hypertension, has developed a new mobile app (phaware365) to help achieve its goal globally through an innovative and engaging strategy. Pulmonary hypertension (PH) is a life-threatening cardiopulmonary disorder characterized by an abnormally high blood pressure…
New data from Phase 3 clinical studies of Genentech’s Esbriet (pirfenidone), a drug developed for the treatment of pulmonary fibrosis (PF), showed the treatment’s efficacy over time. The data presentation, the “Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in…
Watch the video to learn a little bit more about Pulmonary Fibrosis, causes, symptoms and signs. Learn more about PF here: https://bit.ly/1lfMsiZ…
